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Abstract
Background: In China, the pneumococcal conjugate vaccine (PCV7) and the pneumococcal polysaccharide vaccine
(PPSV23) are not offered under the government’s Expanded Program on Immunization and are instead
administered for a fee. PCV7 is more effective and covers more serotypes associated with invasive disease in
children, but is also more expensive, than PPSV23. Because of their expense, there is concern that these vaccines,
especially PCV7, have low uptake particularly among non-locals, migrants from outside of Shanghai. This paper
characterizes the differential coverage of PCV7 and PPSV23 between locals and non-locals in Shanghai, and
illustrates coverage trends over time.
Methods: In this retrospective cohort study, children born between 2005 and 2011 were sampled from the
Shanghai Immunization Program Information System. Bivariate and multivariable analyses examined the
relationships between demographic characteristics, residency status (non-locals vs locals), and vaccination coverage.
Results: PPSV23 coverage (29.8 %) among children over 2 years of age was higher than PCV7 coverage (10.1 %) for
locals and non-locals. Uptake of PCV7 increased substantially after children were 2 years of age. Overall, non-local
populations had higher PPSV23 coverage (OR: 1.34; 98 % CI: 1.22, 1.46) but lower PCV7 coverage (OR: 0.617, 98 % CI:
0.547, 0.695) than locals.
Conclusions: There is a need for increasing overall pneumococcal coverage in Shanghai children, particularly with
the more effective PCV7 vaccine. Morbidity and mortality due to invasive pneumococcal disease for children <1 year of
age are unlikely to be mitigated if the current age-related vaccination patterns are not improved.
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Background
The pathogen Streptococcus pneumoniae (pneumococ-
cus) is the most common cause of pneumonia in chil-
dren worldwide [1], and it is the etiologic agent for
invasive pneumococcal disease (IPD), comprising menin-
gitis, bacteremia, and pneumonia [1]. Globally, there are
14.5 million cases and 826,000 deaths each year due to
IPD in children younger than 5 years. Twelve percent of
these cases occur in China, and approximately 30,000
children <5 years die from IPD there each year [2].
Pneumococcal infections are largely preventable
through routine immunization. There are ninety different
pneumococcal serotypes capable of causing infection in
humans, and the two pneumococcal vaccines currently
available in China cover a number of the most prevalent
strains that cause IPD. The 23-valent pneumococcal poly-
saccharide vaccine (PPSV23) has been available in China
since 1996 and has several drawbacks: it only elicits short-
term immunity, cannot be administered until 2 years of
age, and has a lower efficacy ranging from 60 to 70 % at
preventing IPD [3, 4]. The 7-valent pneumococcal conju-
gate vaccine (PCV7) was introduced to China in 2008, al-
though it was pulled off the market in 2015 because its
import license expired [5]. It protects against fewer sero-
types, but has better efficacy (>90 %) [4], and it can be
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administered earlier, at 6 weeks of age [4]. This moves up
the timeline of protection and represents a major advan-
tage over the PPSV23 since the incidence rate of IPD is
highest in children <2 years of age [4].
PCV7 has had a marked impact on reducing the bur-
den of IPD in countries that have made it widely access-
ible to children through inclusion in their recommended
immunization schedule. In the US, which formally rec-
ommended PCV7 for use in 2000, IPD caused by the se-
rotypes in the vaccine decreased by 94 % (from 15.5 to
1.0 cases per 100,000 population) between 1998 and
2007 [6]. In contrast, neither the conjugated or polysac-
charide pneumococcal formulation of the vaccine has
yet been included in the Chinese Expanded Program on
Immunizations (EPI), unlike many other countries
around the world [7]. China’s reluctance to include ei-
ther pneumococcal vaccine in its EPI is due to a com-
bination of factors, including the high cost of vaccine,
the lack of serotype research on the most prevalent
strains in China, continuing questions regarding the ac-
tual burden of IPD in Chinese children, and concerns
over vaccine efficacy [8].
Similar to in other countries, vaccines on the Chinese
EPI, such as diphtheria-tetanus-pertussis vaccine (DTP),
oral poliomyelitis vaccine, and the measles-containing
vaccines, are fully and publically funded, are mandatory
for school entry, and have higher uptake by the general
public than vaccines not included on the EPI schedule.
Parents are required to pay out of pocket for their chil-
dren’s non-EPI vaccines, including the Haemophilus
influenzae type b vaccine (Hib), rotavirus vaccine, and
varicella vaccine [9]. The PPSV23 vaccine is produced
domestically in China and costs approximately 23 US
dollars whereas the PCV7 vaccine is imported and costs
approximately 130 US dollars per dose (the pneumococ-
cal conjugate vaccine is priced similarly in the United
States [10], though it is covered by insurance). Although
cost is likely to be barrier to pneumococcal vaccine up-
take for everyone in China, it may be particularly prob-
lematic for the non-local population in China, who are
sometimes known as the “floating population,” and
whose presence is rapidly growing in most urban areas
of the country [11].
Non-local families typically relocate from the rural
agrarian areas into the more urban areas of China in
search of increased economic opportunities and repre-
sent one of the largest sustained internal migrations un-
derway globally [12]. These individuals, many of whom
are economically disadvantaged, are classified as non-
locals because they do not possess a local residency per-
mit (hukou), which is required to access many of the
important economic benefits associated with social wel-
fare programs, including employment, education, health-
care, and social security [13–15]. Recent research has
focused on determining whether disparities in access for
non-locals extend to vaccination services even though
the Chinese government provides EPI vaccines free of
charge to all children. A study by Sun et al. (2010) exam-
ined the uptake of four vaccines on the EPI schedule by
non-local populations: hepatitis B vaccine, DTP, oral
poliomyelitis vaccine, and the measles vaccine. Non-
locals had relatively low age-appropriate vaccination,
and the authors suggested this has given rise to a pool of
non-locals who are at higher risk of disease acquisition
and serve as a potential reservoir for ongoing transmis-
sion of vaccine-preventable diseases in China [16].
Moreover, we have found that disparities between non-
locals and locals are greater in regards to non-EPI vac-
cines than EPI vaccines. In a previous analysis of
children <8 years of age living in Shanghai, we found
that the coverage of DTP, an EPI vaccine, was similar
in locals and non-locals, but there was substantially
lower coverage of two non-EPI vaccines (PCV7 and a
Haemophilus influenzae type b vaccine) among non-
locals compared to locals [17].
In this study, we characterize disparities in utilization
of the two pneumococcal vaccines based on residency
status (local vs. non local) of children living in Shanghai.
We assess whether there are differences in coverage in
PCV7 and PPSV23 between local and non-local popula-
tions living in Shanghai, and examine trends in coverage
of PPSV23 and PCV7 over time in children under the
age of 7 years of age. We hypothesize that PCV7 has
lower coverage than PPSV23 due to differentials in price,
that uptake of both vaccines is lower in non-local com-
pared to local populations, and that overage for both of
these vaccines is higher among Shanghai children born
more recently in the study period.
Methods
Data collection
A retrospective cohort was used to assess PCV7 and
PPSV23 coverage by residency status in Shanghai. We
used a sample of children born between 2005 and
2011 from the Shanghai Immunization Program Infor-
mation System (SIPIS) housed at the Shanghai Cen-
ters for Disease Control and Prevention (CDC) in
July 2012. This cohort has been described elsewhere
[17]. SIPIS is an immunization information system,
into which immunization providers throughout
Shanghai upload pediatric vaccination administration and
demographic data. Two districts, Pudong and Minhang,
had their own systems at the time of data collection and
are not included in SIPIS.
Variables
For each child, SIPIS data on sex, residency (local or
non-local), district of residence, birthdate, and dates of
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any vaccination were extracted. Urbanicity included
two categories; the districts of Huangpu, Luwan,
Xuhui, Zhabei, Changning, Jing’an, Putuo, Hongkou,
and Yangpu are considered inner districts while the
districts of Pudong, Minhang, Baoshan, Jiading, Jinshan,
Songjiang, Qingpu, Nanhui, Fengxian, and Chongming
are outer districts.
For both vaccines considered (PCV7 and PPSV23), a di-
chotomous variable was first created based on whether
the child had a record of vaccine administration. Age at
vaccination, the difference between vaccination date and
birthdate, was calculated and categorized separately for
each vaccine. This variable describes the spread of values
for when the child was vaccinated, even though our ana-
lyses only included children old enough to receive the
vaccine at the recommended age (i.e., 6 weeks for
PCV7 and 2 years for PPSV23). For PCV7, the cat-
egories were <6 weeks, 6 weeks to <7 months,
7 months to <12 months, 12 months to <24 months,
and over 24 months. Categories of less than 2 years,
2 to 3 years, and over 3 years were used for PPSV23.
Co-administration of PCV7 was defined as any dose
that was administered at the same time as a diph-
theria-tetanus-pertussis vaccine (DTP), any measles-
containing vaccine, oral polio vaccine dose 1, Hib, rota-
virus vaccine, or varicella vaccine.
We calculated dose 1 coverage but not other measures
(such as dose 2 uptake of PCV7 and PPSV23 or PCV7
series completion) because most children (over two-
thirds) received their pneumococcal vaccinations after
2 years of age, at which point only 1 dose is recom-
mended for both vaccines.
Statistical analysis
Descriptive statistics including counts and proportions
were calculated for each demographic characteristic and
vaccination outcome. Logistic regression models were
separately fit for the outcomes of PCV7 and PPSV23 ad-
ministration. Unadjusted models evaluated the associa-
tions between residency, urbanicity, or birth year and
vaccine administration. The multivariable, adjusted
models included residency, urbanicity, and birth year to-
gether as predictors. Birth year was entered into the
model as a continuous variable. For all regression
models, we constructed 98 % confidence intervals and
evaluated significance of findings based on an α level of
0.02. To assess trends in vaccination over time, PCV7
coverage and PPSV23 coverage were calculated by birth
year and by residency, and the results depicted graphic-
ally in a bar chart. A plot of the cumulative coverage of
PCV7 and PPSV23 across age of the children was strati-
fied by residency to show trends in vaccination coverage
across age. All analyses used SAS version 9.3 (SAS Insti-
tute Inc., Cary, North Carolina).
Ethical statement
This study was deemed exempt from Institutional Re-
view Board oversight at the University of Michigan and
the Shanghai Centers for Disease Control and Preven-
tion because it was limited to analysis of previously col-
lected data for public health purposes.
Results
Initially, 35,463 children were sampled from SIPIS, a
minimum of 5000 from each of seven birth years exam-
ined. A total of 1822 children were removed from the
dataset: 329 because of invalid vaccination dates, i.e.
dates prior to their birth date, and 1493 because they
did not have records of polio vaccine dose 1, DTP dose
1 or hepatitis B vaccine dose 1, 3 vaccines which have
high coverage and for which the absence of records is a
sign of attrition from the dataset. The resulting 33,641
children were all old enough to receive PCV7, and there-
fore formed the PCV7 dataset. The analysis of PPSV23
was limited to the 25,434 children older than 2 years of
age and who had records of DTP dose 4 and measles-
mumps-rubella vaccine, 2 EPI vaccines given before a
child is 2 years of age.
Table 1 shows the study population characteristics.
The total sample of 33,641 children included more males
(53.6 %), greater numbers of non-locals (59.9 %), and
more children from outer districts (68.9 %) than inner
districts. Only 10.1 % of children in the entire study
sample were vaccinated with the first dose of PCV7, and
29.8 % of children had received the first dose of PPSV23.
Among those vaccinated with PCV7, most children
(68.3 %) received the vaccine after 2 years of age, and
the majority of children (70.3 %) who had received
PPSV23 did so between 2 and 3 years of age. The mean
age at vaccine administration was 2.06 years for PCV7
(standard deviation (SD): 1.07) and 2.72 years for
PPSV23 (SD: 0.93).
Few children had PCV7 co-administered with another
vaccine. Only 3.1 % of PCV7 dose 1 administrations oc-
curred at the same time as another vaccine. Including all
4 doses of PCV7, only 3.5 % of these doses were given
simultaneously with another vaccine.
Vaccine coverage among the cohort decreased for
PCV7 in successive years and remained stable for
PPSV23 (Fig. 1). PCV7 coverage was highest for children
born in 2007 (16.6 % local and 13.3 % non-local children
vaccinated) whereas, only 7.0 % of local and 2.6 % of
non-local children were vaccinated in 2011. For PPSV23,
vaccine coverage was between 20 and 30 % for local chil-
dren and between 25 and 40 % for non-local children
across all years.
The plot of cumulative vaccination coverage shows
that coverage of both vaccines increases substantially
after 24 months of age (Fig. 2). By 90 months of age,
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PPSV23 coverage was higher in non-locals (37.2 %) com-
pared to locals (30.7 %), but PCV7 coverage was higher
in locals (16.4 %) than non-locals (11.1 %).
In the logistic regression, the unadjusted and adjusted
models showed similar patterns (Table 2). In the
adjusted model, non-locals had 0.60 times the odds of
PCV7 administration compared to locals (98 % CI: 0.55,
0.66) and outer district children had 0.75 times the odds
of vaccination compared to those in the inner districts
(98 % CI: 0.69, 0.82). Non-locals had 1.28 times the odds
of PPSV23 administration compared to locals (98 % CI:
1.19, 1.36), and those living in the outer districts had
1.23 times higher odds of vaccination than inner district
children (98 % CI: 1.15, 1.32).
Discussion
In a large sample of children from Shanghai, China, we
found uniformly low pneumococcal vaccine coverage for
both the PCV7 and PPSV23 for all birth years; this was
especially true for PCV7 administration in non-locals
and in younger infants. Although Shanghai is one of the
wealthiest subdivisions of China, its PCV7 coverage
levels are similar to those from a 2012 survey of children
aged 1 to 2 years selected from 31 provinces throughout
China in which just 9.91 % had received a dose of PCV
[18]. These figures are in stark contrast to pneumococcal
vaccine coverage in many countries where these vaccines
are included on the EPI schedule; the 2009 US National
Immunization Survey put PCV7 coverage among chil-
dren aged 19–35 months at 92.6 % for ≥3 doses and
80.4 % for ≥4 doses [19]. And, in developing countries
funded through the GAVI Alliance, 19 % of children re-
ceived a third dose of PCV [20].
These estimates of pneumococcal vaccine coverage in
China are far below those estimated for coverage with
EPI vaccines. For example, 98.6 % of children in Tianjin
in 2012 had received measles vaccine dose 1 [21], and
over 97 % of children in Shanghai in 2012 had received
DTP dose 1 [17]. The discrepancy in coverage is likely
due, in part, to the pneumococcal vaccines’ lack of inclu-
sion on China EPI schedule and the need to pay for
them out of pocket. In contrast, EPI vaccines are
mandatory and free to the public. Vaccine cost appears
to be especially important given the higher coverage but
lower cost of PPSV23 compared to PCV7. The $100
price difference between these two pneumococcal vac-
cines could potentially incentivize caregivers to purchase
the less expensive, yet less effective, PPSV23. Nonethe-
less, China has a significant number of childhood IPD
cases, second only to India globally [2], and the high dis-
ease burden, particularly among young infants who are
also most likely to experience severe illness and death, is
unlikely to change without higher vaccination coverage
against PCV7 or PPSV23.
We found pneumococcal vaccine coverage differences
by residency status. The local population had a signifi-
cantly higher PCV7 dose 1 coverage than the non-local
population, although contrary to our initial hypothesis,
non-locals had a higher PPSV23 dose 1 coverage than
Table 1 Distribution of demographic characteristics and
vaccination outcomes of children, Shanghai Immunization
Program Information System, July 2012
PCV7 dataset
(%)
PPSV23 dataset
(%)
Overall 33,641 (100) 25,434 (100)
Sex
Male 18,019 (53.6) 13,655 (53.7)
Female 15,622 (46.4) 11,779 (46.3)
Residency
Local 13,496 (40.1) 11,241 (44.2)
Non-local 20,145 (59.9) 14,193 (55.8)
Urbanicity
Inner 10,453 (31.1) 8477 (33.3)
Outer 23,188 (68.9) 16,957 (66.7)
Birth year
2005 4753 (14.1) 4422 (17.4)
2006 4937 (14.7) 4685 (18.4)
2007 5022 (14.9) 4773 (18.8)
2008 5014 (14.9) 4724 (18.6)
2009 5030 (15.0) 4654 (18.3)
2010 4818 (14.3) 2176 (8.6)
2011 4067 (12.1) -
Vaccinated with PCV7 Dose 1
Yes 3395 (10.1) -
No 30,246 (89.9) -
Age at PCV7 Dose 1 administrationa
<6 weeks of age 5 (0.2) -
6 weeks to <7 months of age 418 (12.3) -
7 months to <12 months of age 291 (8.6) -
12 months to <24 months of age 362 (10.7) -
Over 24 months of age 2319 (68.3) -
Vaccinated with PPSV23 Dose 1
Yes - 7583 (29.8)
No - 17,851 (70.2)
Age at PPSV23 Dose 1 administrationb
<2 years of age - 118 (1.6)
2 to <3 years of age - 5328 (70.3)
Over 3 years of age - 2137 (28.2)
PCV7 pneumococcal conjugate vaccine, PPSV23 pneumococcal
polysaccharide vaccine
aOnly includes the subpopulation of n = 3395 who were vaccinated for PCV7
bOnly includes the subpopulation of n = 7583 who were vaccinated for PPSV23
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Fig. 1 Coverage of pneumococcal conjugate vaccine (PCV7) and pneumococcal polysaccharide vaccine (PPSV23) by birth year and residency
status, Shanghai Immunization Program Information System, July 2012
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Fig. 2 Cumulative vaccination coverage of pneumococcal conjugate vaccine (PCV7) and pneumococcal polysaccharide vaccine (PPSV23) by
residency status, Shanghai Immunization Program Information System, July 2012
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local populations. Because locals generally have higher
household incomes than non-locals [14], they may be
more able to afford the higher cost of the PCV7 vaccine
while non-locals may opt instead for the less expensive
PPSV23 alternative. As a non-conjugated polysaccharide
vaccine, PPSV23 has lower efficacy than for PCV7
(>90 % for PCV7 vs 60–70 % for PPSV23) [3, 4], and
lower coverage with PCV7 may result in non-local chil-
dren remaining more vulnerable to pneumococcal infec-
tion, even with PPSV23 vaccination. For children born
later in the study, in 2009 and 2010, coverage with any
pneumococcal vaccination was higher for non-locals
than locals because of substantially higher coverage of
PPSV23. We do not have information on why non-
locals, characterized but economic disadvantage vis-à-vis
locals, had higher PPSV23 coverage in these years but it
could result from non-locals having greater worry about
disease and less concern about side effects than locals.
As a conjugated vaccine, PCV7 can be administered at
younger ages compared to PPSV23, although we found
most children were vaccinated against pneumococcus
with either vaccine when over 2 years of age. The PCV7
was only approved for use in China after 2008, and earl-
ier birth cohorts would have been unable to receive this
vaccine at younger ages. There was a decrease in PCV7
coverage for later birth years, perhaps because parents
became accustomed to vaccinating their children later,
and children in later birth cohorts had not yet reached
2 years of age. Vaccination at earlier ages is preferred as
it provides protection against more serious disease in
young infants, but that also necessitates more doses of
PCV7 for series completion and long-lasting immunity.
It may be that parents object to earlier vaccination on fi-
nancial grounds despite the risk of more serious disease
for younger children or it could be that vaccinating at an
earlier age is not an option because the manufacturer’s in-
structions for PCV7 recommend against co-administered
with any other vaccine, although there is no such contra-
indication in the United States or Europe. Moreover, the
EPI schedule for children under 1 year of age in China,
like many other countries, is complex and involves many
vaccinations and parents may push back against additional
shots for their children.
The choice of promoting PCV7 or PPSV23 is an import-
ant one, because healthy children are not recommended
to be immunized with both vaccines. Because of the inher-
ent immunological limitations to PPSV23, it is not recom-
mended for routine childhood use in the United States
[22], and international pneumococcal control has rather
focused on conjugate vaccines [7]. Therefore, we would
encourage adoption of PCV7 over PPSV23, although data
on the distribution of pneumococcal serotypes among
IPD cases in China (which are currently lacking [23])
could mitigate this recommendation if proportionally few
cases result from the serotypes in the 7-valent vaccine.
This study has several notable limitations and
strengths. The database of SIPIS lacks data for Pudong
and Minhang, two populous districts in Shanghai which
may reduce the representativeness of the data and bias
overall coverage estimates. Because SIPIS was only im-
plemented after 2010, information for children in prior
years may be limited. This database only includes chil-
dren who receive services in immunization clinics and
others would not be present in the system, which may
result in vaccination coverage overestimation, particu-
larly for non-locals who probably are less likely to access
these services than locals. Attrition can also occur in
SIPIS; families who move out of Shanghai are not neces-
sarily removed from the system. We tried to limit this
bias by creating a dataset which only includes individuals
who received sentinel vaccines. Lastly, this study had a
narrow time frame and because PCV7 was introduced in
2008 in Shanghai, we were unable to evaluate longer-
term trends in uptake. A follow-up study would permit
assessment of trends over time, particularly between lo-
cals and non-locals and in the age at administration of
pneumococcal conjugate vaccine dose 1. The strengths
of this study included data involving a large number
of children were obtained from a well-established
immunization information system, and so we were
able to obtain accurate information on dates of vac-
cination over a number of years.
Conclusions
We found low vaccination levels with both pneumococ-
cal vaccines among children in Shanghai, China over a
Table 2 Odds ratios (OR) and 98 % confidence intervals (CI) for administration of the first dose of pneumococcal conjugate
vaccine (PCV7) or pneumococcal polysaccharide vaccine (PPSV23) in children; Shanghai Immunization Program Information
System, July 2012
PCV7 administration PPSV23 administration
Unadjusted model
OR (98 % CI)
Adjusted model
OR (98 % CI)
Unadjusted model
OR (98 % CI)
Adjusted model
OR (98 % CI)
Non-local vs local 0.57 (0.52, 0.62) 0.60 (0.55, 0.66) 1.33 (1.25, 1.42) 1.28 (1.19, 1.36)
Outer vs inner district 0.67 (0.61, 0.73) 0.75 (0.69, 0.82) 1.30 (1.21, 1.40) 1.23 (1.15, 1.32)
Birth year (continuous) 0.85 (0.83, 0.87) 0.86 (0.84, 0.88) 1.05 (1.03, 1.07) 1.04 (1.02, 1.06)
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7-year span of time. The low coverage could help ex-
plain the continuing high burden of childhood pneumococ-
cal disease observed throughout China if similar patterns in
vaccine coverage characterize the remainder of the country.
Although PPSV23 coverage was comparable or higher in
non-locals compared to locals, PCV7 coverage was uni-
formly lower among non-local populations for all years, po-
tentially placing them at higher risk of disease due to the
lower efficacy of the polysaccharide vaccine. Age at initial
vaccination was above that recommended for both PCV7
and PPSV23, leaving young infants susceptible to disease at
a time that they are especially vulnerable to more severe ill-
ness and death. Shanghai should consider the addition of
PCV7 to the EPI schedule to increase coverage. However,
any targeted immunization program aimed at preventing
pneumococcal disease should ensure equitable access to
vaccines for non-locals and locals alike and needs to be
provided at an early age so that the burden of invasive
pneumococcal disease is reduced among the very young.
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